# Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population

> **NCT00137033** · PHASE4 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 605 (—)

## Conditions studied

- Peptic Ulcers

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Naproxen
- **DRUG:** ASA

## Key facts

- **NCT ID:** NCT00137033
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 605 (—)
- **Last updated:** 2021-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00137033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00137033, "Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00137033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*